• Metronidazole (B1976): OAT3 Inhibition & Anaerobe Research U

  2026-05-20

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) is a nitroimidazole antibiotic and a validated OAT3 inhibitor, widely used in research targeting anaerobic bacteria and protozoa. Its inhibition of organic anion transporters is quantitatively characterized, enabling precise modulation of drug-drug interactions in laboratory settings.

• Exo1: Advancing Membrane Trafficking Inhibition in Oncology

  2026-05-20

  This article explores Exo1 (methyl 2-(4-fluorobenzamido)benzoate) as a next-generation exocytic pathway inhibitor, integrating mechanistic insights with strategic guidance for translational researchers. By connecting Exo1’s unique mode of action to the latest advances in tumor extracellular vesicle (TEV) biology and referencing recent landmark studies, we outline a new paradigm for dissecting membrane trafficking and developing antimetastatic strategies.

• Decoding Fluconazole Resistance: Mechanisms and Translationa

  2026-05-19

  This thought-leadership article examines the molecular underpinnings of fluconazole resistance in Candida albicans, focusing on the intersection of ergosterol biosynthesis inhibition, autophagy-driven biofilm adaptation, and translational research approaches. Drawing on recent mechanistic studies and validated protocols, we provide strategic guidance for researchers aiming to advance antifungal drug resistance research and optimize experimental design using APExBIO's Fluconazole.

• Lenalidomide & Epigenetic Synergy: New Horizons in Myeloma R

  2026-05-19

  Explore how Lenalidomide (CC-5013) is transforming multiple myeloma research by integrating robust immunomodulation with cutting-edge epigenetic strategies. This article provides translational researchers with mechanistic insights, protocol guidance, and a forward-looking perspective on immune-epigenetic combination therapies—grounded in the latest evidence and practical workflows.

• DDI2-NFE2L1 Axis Protects Against Ferroptosis via UPS Activa

  2026-05-18

  This study elucidates how the DDI2-mediated activation of NFE2L1 safeguards cells from ferroptosis by restoring proteasome function. The findings not only clarify mechanisms of regulated cell death but also highlight potential targets for sensitizing cancer cells to ferroptosis-based therapies.

• M344: Epigenetic Intervention in Cancer and HIV Latency Rese

  2026-05-18

  Explore M344, a potent histone deacetylase inhibitor, with in-depth analysis of its role in chromatin remodeling, cancer cell proliferation inhibition, and HIV latency research. This article offers a unique scientific perspective and protocol insights for advanced experimental design.

• PQQ Activates Nrf2–IGF1R Axis to Protect Against Age-Related

  2026-05-17

  This study demonstrates that long-term dietary pyrroloquinoline quinone (PQQ) alleviates age-related osteoarthritis in mice by activating Nrf2-mediated antioxidant defense and upregulating IGF1R, thus reducing oxidative damage and preserving cartilage. The findings highlight a mechanistic link between redox signaling and cartilage integrity, providing a promising disease-modifying strategy for osteoarthritis.

• Berberrubine Inhibits Thrombosis via Vitamin K Cycle Modulat

  2026-05-16

  This study establishes berberrubine as a potent inhibitor of thrombosis in mice by targeting the vitamin K catalytic cycle, using integrated metabolomics and molecular docking. The research provides a mechanistic basis for potential development of safer antithrombotic agents and informs comparative research on established anticoagulants such as Dabigatran.

• Metoprolol Tartrate: β1 Blockade Redefining Translational Re

  2026-05-15

  Explore how selective β1-adrenergic receptor inhibition with Metoprolol Tartrate is transforming cardiovascular and hematopoietic research. This thought-leadership article delivers mechanistic depth, translational context, and actionable strategy—anchored in the latest evidence and protocol guidance for forward-thinking investigators.

• Oral Dextran Microgels for Targeted Colon Cancer Therapy: A

  2026-05-15

  Lu et al. (2022) developed a dual-targeted, enzyme-responsive dextran microgel system for oral delivery of cisplatin and SPION-loaded lipid nanoparticles, achieving selective colon accumulation and significant tumor suppression in murine models. This innovative approach addresses longstanding challenges of oral chemotherapeutic stability, bioavailability, and site-specific delivery in colorectal cancer treatment.

• Mechanism-Based Inactivation of CYP2D6 by Berberrubine Chlor

  2026-05-14

  This article examines the newly identified irreversible inhibition of the drug-metabolizing enzyme CYP2D6 by berberrubine, a metabolite of berberine, based on recent mechanistic studies. The findings have significant implications for drug–herb interactions and the design of cancer and metabolic research experiments involving Berberrubine chloride.

• MDL 28170: Calpain Inhibitor Workflows for Neuroprotection &

  2026-05-14

  MDL 28170 sets the benchmark for selective calpain inhibition, offering nanomolar potency, brain penetrance, and versatile utility across neuroprotection, apoptosis, and infection models. This article translates the latest mechanistic evidence—including BDNF/TrkB pathway rescue—into actionable protocols and troubleshooting insights for advanced biomedical research.

• Pyridostatin TFA in Precision G-Quadruplex Targeting for Can

  2026-05-13

  Explore how Pyridostatin TFA enables next-generation research in telomere biology, G-quadruplex modulation, and targeted cancer cell growth inhibition. This article delivers a unique, mechanistic analysis with actionable insights for advanced DNA secondary structure research.

• PR-619: Practical Guide to Broad-Spectrum DUB Inhibition

  2026-05-13

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor designed for broad suppression of cysteine-dependent DUBs in cell-based assays. It is best suited for ubiquitination pathway research, autophagy activation assays, and studies in cancer or neurodegenerative disease models. Avoid use when aqueous or ethanol solubility is required, or where DUB selectivity is critical.

• HyperScript First-Strand cDNA Synthesis Kit: Precision for L

  2026-05-12

  Discover how the HyperScript First-Strand cDNA Synthesis Kit empowers researchers to achieve high-fidelity cDNA synthesis from challenging RNA templates. Learn why its advanced enzyme and primer design make it uniquely suited for low copy gene reverse transcription and robust qPCR workflows.

693 records 13/47 page Previous Next First page 上5页 1112131415 下5页 Last page